Stock Alert: Alterity Therapeutics Surges To New 52-week High

Shares of Alterity Therapeutics Limited (ATHE) are gaining almost 144 percent or $1.94 in Tuesday's morning trade at $3.29, after earlier touching a new 52-week high of $3.84.

Monday, Alterity Therapeutics said that new clinical and experimental pharmacology data for its lead drug candidate ATH434 has been selected for presentation at the 2020 International Congress of Parkinson's Disease and Movement Disorders (MDS 2020) and the American Neurological Association's 2020 Annual Meeting (ANA 2020).

ATH434 is being developed for the treatment of Multiple System Atrophy or MSA, a Parkinsonian disorder, and has been successfully studied in a phase I study for MSA.

Alterity Therapeutics said that new data from an experiment testing of ATH434 in an animal model of MSA independently confirmed and extended previous findings demonstrating that ATH434 reduces a-synuclein pathology, preserves neurons, and improves motor performance. The data will be presented at ANA 2020.

Alterity Therapeutics has traded in a range of $0.28 to $3.84 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT